Tom Dubensky

35-year Biotech/entrepreneur career including 15-years of strategic C-level leadership as CEO, President and CSO ranging from private, venture-backed start-up companies to public Biotechnology companies. Demonstrated track record of leveraging deep scientific and development experience coupled with business strategy and capital fundraising, as evidenced by leading or co-leading fundraising through venture capital and corporate partnerships, for Series A, Series B, cross-over rounds to IPO. Competent in executing corporate strategy collaboratively with board of directors and executive teams to build value through pipeline/portfolio management, collaboration, corporate partnerships and interaction with both buy/sell side investors. As Director, VP, CSO and CEO, led the development of multiple oncology programs from research through early-stage clinical development, including discovery, lead or development candidate selection, translation, IND-enabling studies (tox, CMC), regulatory, IND submissions/approvals and extensive FDA interactions. Established record of advancing first-in-class agents to clinical evaluation in oncology, immunology and vaccines. Diverse technical background ranging from complex biologics to small molecules. Inventor on >50 issued US patents and author on >85 publications related to development of platforms/technologies/small molecule-based therapy and clinical trials. Pub Med: https://pubmed.ncbi.nlm.nih.gov/?term=dubensky%20t.&sort=date Google scholar: https://scholar.google.com/citations?hl=en&user=e4hFwsgAAAAJ Google patents: https://patents.google.com/?q=(dubensky+t)&oq=dubensky+t